Travere Therapeutics Third Quarter 2026 Earnings Results - TRAVERE THERAPEUTICS INC

Financial Performance:

• Third Quarter 2026 Total U.S. Net Product Sales reached $220.2 million, with Filspari sales driving growth at $200.2 billion (120% YoY increase), marking the first time quarterly net product sales surpassed $200 million.
• Additional net product sales of $20.4 million were generated from Iola and Iola EC.
• Total Revenue, including $4.4 million in licensing/collaboration revenue, stood at $224.6 million.
• Total GAAP R&D and SG&A expenses were $168.7 million, significantly impacted by a $113.1 million IPR&D expense related to the Everest licensing agreement closing.
• Cash, cash equivalents, and marketable securities balance was $471.8 million as of September 30, 2026.
• Gross-to-net discounts for Filspari were approximately 8% in the quarter due to one-time benefits, with full-year expectations in the mid-20% range; Q4 is expected to have a $8 million revenue reduction due to specialty pharmacy inventory normalization.

Guidance and Future Outlook:

• Management reaffirms the long-term goal of achieving or exceeding $3 billion in annual Filspari sales by 2033.
• Filspari patent portfolio extended through 2037 with new issuances for IgA nephropathy and allowance for FSGS methods.
• Q4 net sales guidance expects a temporary reduction of ~$8 million as specialty pharmacies dispense current inventory; sequential growth in patient starts is expected to resume post-Q4.
• Pipeline milestones include U.S. IND submission for Sivarabrutinib (likely Membranous Nephropathy as priority) by year-end, with late-stage planning underway.
• Phase 3 Harmony study enrollment for PEG-2-batinase (HCU) is progressing with top-line results targeted for the second half of 2027.
• SPARCS study enrollment in FSGS/IgA post-transplant is complete, with data expected in 2027; SPARlight study initiation anticipated later in 2026.

Business Segments and Product Lines:

• Filspari (IgA Nephropathy): Remains the most prescribed therapy; high patient persistence and adherence observed; physicians increasingly viewing it as a foundational kidney-targeted treatment to be combined with B-cell therapies.
• Filspari (FSGS): Strong early launch performance with high adoption; ~40% of new prescribers are new to Filspari; expansion into pediatric patients (8+) showing consistent utilization (~10% of starts).
• PEG-2-batinase: Phase 3 development for classical Homocystinuria (HCU) advanced; potential first disease-modifying therapy targeting CBS enzyme deficiency.
• Sivarabrutinib: Oral BTK inhibitor targeting immune-mediated kidney diseases; early data in primary membranous nephropathy shows rapid anti-PLA2R antibody reduction; IND submission planned for Q4.

Market and Competitive Landscape:

• IgA Nephropathy (IgAN) market is evolving with new immune-directed therapies (e.g., B-cell inhibitors) replacing steroids; Filspari positioned as the preferred endothelin receptor antagonist and foundational kidney-targeted therapy.
• KDIGO guidelines support combination strategies (Filspari + SGLT2 + B-cell therapy) to achieve complete proteinuria remission; Filspari shown to be effective even in patients below 1.5g proteinuria (70% of patient population).
• FSGS market sees high demand and rapid payer formulary adoption; physicians are encouraged to broaden treatment beyond high proteinuria cases as experience grows.
• HHS Kidney Care National Plan announced, highlighting federal focus on earlier diagnosis and intervention for rare kidney diseases, potentially expanding the addressable patient pool.

Risks and Challenges:

• Seasonality impacts (e.g., summer dip) and competitive pressures in the IgAN market may cause quarter-over-quarter variability in new patient starts.
• New market entrants require physicians to manage increased treatment sequencing and combination complexity.
• Inventory normalization at specialty pharmacies resulted in a temporary $8 million revenue drag in Q4 expectations.
• Execution risk in translating the HHS National Plan into actionable diagnostic/treatment pathways.

Management Commentary and Tone:

• CEO Eric Dube announced his upcoming departure in December; expressed high confidence in the company's future under new leadership (Bradley joining Dec 1st) and the team's ability to execute.
• Tone is exceptionally confident regarding commercial momentum, patient persistence, and the durability of the Filspari franchise despite increased competition.
• Emphasis on "disease-modifying" potential and the shift toward earlier treatment initiation supported by new clinical data.

Analyst Questions and Answers:

• FSGS Conversion: Management confirmed FSGS time-to-paid-prescription conversion is rapid, nearly matching IgAN levels, with ~80% conversion rates observed.
• Q4 Trends: While providing no specific numerical guidance, executives noted strong demand in October and expect continued sequential growth in patient starts post-seasonality.
• Sequencing: Clarified that B-cell therapies are generally added on top of Filspari rather than replacing it; Filspari remains preferred for kidney protection and is often the first branded therapy initiated.
• Pediatrics: Pediatric utilization in FSGS is consistent with trial data (~10% of starts) with no access or payer hurdles compared to adults.
• Dosing: Filspari titration to the 800mg dose in FSGS is proceeding as expected with good compliance, consistent with the DUPLEX trial.

Other Key Points:

• New clinical data presented at ASN Kidney Week supports Filspari's dual endothelin/angiotensin blockade mechanism, showing superior proteinuria reduction and eGFR preservation compared to eribasin.
• SPARTAN two-year data highlighted 75% complete remission rates in treatment-naive patients when Filspari is used as first-line therapy.
• The Everest licensing agreement for Sivarabrutinib became effective, with the $112.5 million upfront payment recognized as IPR&D expense.